This review summarizes clinical, laboratory, and pathological data regarding pulmonary toxicity associated with antineoplastic drugs to aid practicing physicians.
Answers are grounded in this paper and cite their sources.
May aid clinician recognition of antineoplastic pulmonary toxicity; leaves open need for prospective incidence and management studies.
Pulmonary toxicity caused by antineoplastic drugs is becoming a more frequently recognized entity, and the number of drugs known or suspected of causing this disease is steadily increasing. In general, the initial clinical appearance includes both constitutional signs of malaise and fever, as well as pulmonary complaints. Some clinical signs may suggest a particular drug as the cause. The pathological condition also is generally nonspecific, but some clues may be present histologically that help define the causal agent. This is a review of the antineoplastic drugs that are associated with pulmonary toxicity. Clinical, laboratory, and pathological data are presented as useful information for practicing physicians. Although therapeutic maneuvers are limited, these are discussed with regard to each drug.
No takes yet. Share an insight, caveat, or question.
Gerald Batist (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: